Amgen Inc. - Product Pipeline Review - 2016

  • ID: 3691127
  • Company Profile
  • 251 pages
  • Global Markets Direct
  • Amgen Inc.
1 of 4
Amgen Inc. - Product Pipeline Review - 2016

Summary

‘Amgen Inc. - Product Pipeline Review - 2016’, provides an overview of the Amgen Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Amgen Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Amgen Inc.
- The report provides overview of Amgen Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Amgen Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Amgen Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Amgen Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Amgen Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amgen Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Amgen Inc. Snapshot

Amgen Inc. Overview

Key Information

Key Facts

Amgen Inc. - Research and Development Overview

Key Therapeutic Areas

Amgen Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Amgen Inc. - Pipeline Products Glance

Amgen Inc. - Late Stage Pipeline Products

Amgen Inc. - Clinical Stage Pipeline Products

Amgen Inc. - Early Stage Pipeline Products

Amgen Inc. - Drug Profiles

adalimumab biosimilar

blinatumomab

darbepoetin alfa

denosumab

etanercept

etelcalcetide hydrochloride

romiplostim

AMG-334

bevacizumab biosimilar

evolocumab

fulranumab

panitumumab

rituximab biosimilar

romosozumab

trastuzumab biosimilar

trebananib

abrilumab

AMG-319

AMG-337

AMG-557

AMG-714

AMG-899

ganitumab

omecamtiv mecarbil MR

rilotumumab

tezepelumab

AMG-232

talimogene laherparepvec

AMG-172

AMG-208

AMG-211

AMG-224

AMG-228

AMG-282

AMG-301

AMG-330

AMG-357

AMG-581

AMG-592

AMG-595

AMG-780

AMG-811

AMG-820

AMG-876

AMG-900

AMG-XXX

infliximab biosimilar

pasotuxizumab

solitomab

AM-1638

AM-3189

AM-6226

AM-7209

AM-8553

AM-9514

AMG-0696

AMG-161

AMG-1694

AMG-176

AMG-3969

AMG-511

AMG-570

AMG-8718

AMG-986

Biosimilar 1 for Undisclosed Indication

Biosimilar 2 for Undisclosed Indication

Biosimilar 3 for Undisclosed Indication

Calcimimetic-18

cetuximab biosimilar

Drug for Atherosclerosis

Drugs to Inhibit FGF23 for Bone Disorders

Morpholinone-27

Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases

Recombinant Protein to Agonize FGFR for Type 2 Diabetes

Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes

Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes

Small Molecule to Agonize GPR119 for Undisclosed Indication

Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication

Small Molecule to Agonize GPR142 for Type 2 Diabetes

Small Molecule to Antagonize EP2 Receptor for Alzheimer Disease

Small Molecule to Inhibit BACE1 for Alzheimer's Disease

Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis

Small Molecule to Inhibit PI3K/mTOR for Cancer

Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease

Small Molecules to Inhibit BACE1 for Alzheimer Disease

Small Molecules to Inhibit PDE10A for Neurological Diseases

Small Molecules to Inhibit PI3K Delta for Inflammation

XmAb-13243

XmAb-13551

AA-71

Drugs for Inflammatory Bowel Disease

Monoclonal Antibodies for Cancer and Inflammation

Morpholinone-10

Morpholinone-16

Small Molecules to Inhibit CDC7 kinase for Cancer

Small Molecules to Inhibit IRAK-4 for Inflammation

Small Molecules to Inhibit NIK for Multiple Myeloma

Small Molecules to Inhibit Tankyrase for Cancer

Amgen Inc. - Pipeline Analysis

Amgen Inc. - Pipeline Products by Target

Amgen Inc. - Pipeline Products by Route of Administration

Amgen Inc. - Pipeline Products by Molecule Type

Amgen Inc. - Pipeline Products by Mechanism of Action

Amgen Inc. - Recent Pipeline Updates

Amgen Inc. - Dormant Projects

Amgen Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Amgen Inc. - Company Statement

Amgen Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Amgen Inc. - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Amgen Inc., Key Information

Amgen Inc., Key Facts

Amgen Inc. - Pipeline by Indication, 2016

Amgen Inc. - Pipeline by Stage of Development, 2016

Amgen Inc. - Monotherapy Products in Pipeline, 2016

Amgen Inc. - Partnered Products in Pipeline, 2016

Amgen Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Amgen Inc. - Out-Licensed Products in Pipeline, 2016

Amgen Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Amgen Inc. - Pre-Registration, 2016

Amgen Inc. - Filing rejected/Withdrawn, 2016

Amgen Inc. - Phase III, 2016

Amgen Inc. - Phase II, 2016

Amgen Inc. - Phase I, 2016

Amgen Inc. - Preclinical, 2016

Amgen Inc. - Discovery, 2016

Amgen Inc. - Pipeline by Target, 2016

Amgen Inc. - Pipeline by Route of Administration, 2016

Amgen Inc. - Pipeline by Molecule Type, 2016

Amgen Inc. - Pipeline Products by Mechanism of Action, 2016

Amgen Inc. - Recent Pipeline Updates, 2016

Amgen Inc. - Dormant Developmental Projects,2016

Amgen Inc. - Discontinued Pipeline Products, 2016

Amgen Inc., Other Locations

Amgen Inc., Subsidiaries

Amgen Inc., Key Manufacturing Facilities

List of Figures

Amgen Inc. - Pipeline by Top 10 Indication, 2016

Amgen Inc. - Pipeline by Stage of Development, 2016

Amgen Inc. - Monotherapy Products in Pipeline, 2016

Amgen Inc. - Partnered Products in Pipeline, 2016

Amgen Inc. - Out-Licensed Products in Pipeline, 2016

Amgen Inc. - Pipeline by Top 10 Target, 2016

Amgen Inc. - Pipeline by Route of Administration, 2016

Amgen Inc. - Pipeline by Molecule Type, 2016

Amgen Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll